文献速递消化系统肿瘤

结直肠癌中对KRASG12C-EGFR抑制获得性耐药的分子特征

Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer.
PubMed 文献 · Cancer Discov · 2023-01-01

该研究利用细胞系、患者来源异种移植瘤和患者样本,发现KRASG12C与EGFR抑制剂联合治疗结直肠癌的获得性耐药主要由阻止ERK信号抑制的异质性改变所致,其中KRASG12C扩增是随临床进展而升高的复发性耐药机制,停药后耐药细胞发生癌基因诱导的衰老,靶向衰老反应可能克服耐药。

要点

  • KRASG12C-EGFR抑制的临床耐药主要阻止ERK信号抑制,多数耐药机制为亚克隆性。
  • KRASG12C扩增是随临床进展而升高的复发性耐药机制。
  • 停药后KRASG12C扩增耐药细胞发生癌基因诱导的衰老,靶向衰老反应可能克服获得性耐药。

核心结论

  • KRASG12C-EGFR抑制的获得性耐药主要由阻止ERK信号抑制的异质性改变所致,KRASG12C扩增是随临床进展升高的复发性耐药机制,停药后耐药细胞发生癌基因诱导的衰老,靶向衰老反应可能克服获得性耐药。

研究设计与样本

  • 使用细胞系、患者来源异种移植瘤和患者样本进行分子特征分析。
  • 对治疗中的患者血液样本进行连续分析。

主要发现

  • 检测到推测的耐药改变呈异质性模式,主要预期在疾病进展时阻止药物对ERK信号的抑制。
  • 连续分析患者血液样本显示,大多数耐药改变以低频率检出,而KRASG12C扩增是随临床进展而升高的复发性耐药机制。
  • 停药后,KRASG12C扩增的耐药细胞发生癌基因诱导的衰老,进展患者的循环DNA中该改变水平快速下降。
  • 在这种新状态下,由于mTOR信号升高,恢复用药无效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: With the combination of KRASG12C and EGFR inhibitors, KRAS is becoming a druggable target in colorectal cancer. However, secondary resistance limits its efficacy. Using cell lines, patient-derived xenografts, and patient samples, we detected a heterogeneous pattern of putative resistance alterations expected primarily to prevent inhibition of ERK signaling by drugs at progression. Serial analysis of patient blood samples on treatment demonstrates that most of these alterations are detected at a low frequency except for KRASG12C amplification, a recurrent resistance mechanism that rises in step with clinical progression. Upon drug withdrawal, resistant cells with KRASG12C amplification undergo oncogene-induced senescence, and progressing patients experience a rapid fall in levels of this alteration in circulating DNA. In this new state, drug resumption is ineffective as mTOR signaling is elevated. However, our work exposes a potential therapeutic vulnerability, whereby therapies that target the senescence response may overcome acquired resistance. SIGNIFICANCE: Clinical resistance to KRASG12C-EGFR inhibition primarily prevents suppression of ERK signaling. Most resistance mechanisms are subclonal, whereas KRASG12C amplification rises over time to drive a higher portion of resistance. This recurrent resistance mechanism leads to oncogene-induced senescence upon drug withdrawal and creates a potential vulnerability to senolytic approaches. This article is highlighted in the In This Issue feature, p. 1.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Yaeger R, Mezzadra R, Sinopoli J, et al. Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal Cancer. Cancer Discov. 2023. PMID: 36355783. doi:10.1158/2159-8290.CD-22-0405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。